Literature DB >> 26160114

Probing the 'bipolar' nature of the carbonic anhydrase active site: aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms.

Mikhail Krasavin1, Mikhail Korsakov2, Mikhail Dorogov2, Tiziano Tuccinardi3, Nurcan Dedeoglu4, Claudiu T Supuran5.   

Abstract

A series of potent inhibitors of human carbonic anhydrase (CA) isoforms I and II has been prepared via a direct, chemoselective sulfochlorination of a range of 1,3-oxazolyl benzenes and thiophenes, followed by primary sulfonamide synthesis. The latter functionality is a known zinc-binding group (ZBG) responsible for anchoring the inhibitors to the CA's zinc metal ion. The compound's periphery as well as the overall scaffold geometry was designed to enable optimal interactions with the two distinct sides of the enzyme's active site, one of which is lined with hydrophobic residues and while the other is predominantly hydrophilic. As a result, several compounds inhibiting the therapeutically important cytosolic CA I and CA II in picomolar range have been identified. These compounds are one of the most potent CA inhibitors identified to-date. Not only the remarkable (>10 000-fold), cytosolic CA I and CA II selectivity vs. the membrane-bound CA IX and CA XII isoforms, but also the pronounced CA II/I selectivity observed in some cases, allow considering this series as a set of isoform-selective chemical biology tools and promising starting points for drug candidate development.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  1,3-oxadiazol-5-yl aromatics; Anti-glaucoma drugs; Carbonic anhydrase inhibitors; Chemoselective sulfochlorination; Drug discovery; Isoform selectivity

Mesh:

Substances:

Year:  2015        PMID: 26160114     DOI: 10.1016/j.ejmech.2015.06.022

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  5 in total

1.  PO-322 exerts potent immunosuppressive effects in vitro and in vivo by selectively inhibiting SGK1 activity.

Authors:  Yi Lai; Xing-Yan Luo; Hui-Jie Guo; Si-Yu Wang; Jing Xiong; Shu-Xia Yang; Li-Mei Li; Qiang Zou; Chun-Fen Mo; Yan-Tang Wang; Yang Liu
Journal:  Br J Pharmacol       Date:  2020-02-11       Impact factor: 8.739

2.  Synthesis, molecular modelling and QSAR study of new N-phenylacetamide-2-oxoindole benzensulfonamide conjugates as carbonic anhydrase inhibitors with antiproliferative activity.

Authors:  Mona F Said; Riham F George; Andrea Petreni; Claudiu T Supuran; Nada M Mohamed
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

3.  5-(Sulfamoyl)thien-2-yl 1,3-oxazole inhibitors of carbonic anhydrase II with hydrophilic periphery.

Authors:  Stanislav Kalinin; Alexander Kovalenko; Annika Valtari; Alessio Nocentini; Maxim Gureev; Arto Urtti; Mikhail Korsakov; Claudiu T Supuran; Mikhail Krasavin
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

4.  Development of a Fingerprint-Based Scoring Function for the Prediction of the Binding Mode of Carbonic Anhydrase II Inhibitors.

Authors:  Giulio Poli; Vibhu Jha; Adriano Martinelli; Claudiu T Supuran; Tiziano Tuccinardi
Journal:  Int J Mol Sci       Date:  2018-06-23       Impact factor: 5.923

5.  Further validation of strecker-type α-aminonitriles as a new class of potent human carbonic anhydrase II inhibitors: hit expansion within the public domain using differential scanning fluorimetry leads to chemotype refinement.

Authors:  Mikhail Krasavin; Stanislav Kalinin; Sergey Zozulya; Anastasia Griniukova; Petro Borysko; Andrea Angeli; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.